Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia Quality of Care
Researchers from Georgetown University, Center for Cancer and Blood Disorders describe findings in anemia quality of care
June 26th, 2007
Research findings, "The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia," are discussed in a new report. "Chemotherapy-induced anemia (CIA) may substantially impact the health-related quality of life (HRQoL) of older cancer patients. This exploratory analysis evaluated the effect of darbepoetin alfa administered as a fixed dose (300 microg) every 3 weeks (Q3W) on hematologic outcomes, HRQoL, and safety in older (>or=65 years old) versus younger (<65 years old) patients with CIA (hemoglobin <11 g/dl)," investigators in the United States report. "Patients...
Source: Drug Law Weekly (2007-06-26)
|
